Posted in | News | Biomaterials | Sustainability

Bio-Based PBT Made Using Renewable Feedstock-Based BDO

Lanxess and Genomatica announce that Lanxess has run a production campaign of bio-based PBT in Lanxess’ world-scale production plant using 20 metric tons of bio-based BDO made with Genomatica’s commercially-proven process. This BDO fully complied with the demanding Lanxess specifications for petro-based BDO allowing a direct feed of 100 percent bio-based BDO into the continuous production process.

Lanxess used their world-scale production plant to make bio-based PBT from 20 tons of bio-based BDO made with Genomatica’s process technology. Shown here, the PBT plant at Hamm-Uentrop, Germany, used by Lanxess for this conversion.

The properties and the quality of the resulting bio-based PBT are fully equivalent to conventional petro-based PBT with regard to all tested parameters. The world-scale PBT plant, with a capacity of 80,000 tons per year, is located in Hamm-Uentrop, Germany and operated as a joint venture in which Lanxess has a share of 50 percent

Genomatica’s BDO process technology converts sugars – a renewable feedstock – into the major chemical BDO in a patented, ‘direct’ fermentation process.

“We were excited to validate the bio-based BDO made with Genomatica’s process as a one-to-one replacement for petro-based BDO for the production of our PBT,” said Hartwig Meier, Head of Global Product and Application Development of the High Performance Materials Business Unit of Lanxess. “This is a strong signal to the market and a tremendous step forward in our future plans to offer our high-tech plastic Pocan in a bio-based version, too. Due to its unchanged properties Pocan compounds based on bio-based PBT can directly be used in established application fields such as automotive or electro & electronics area. This fits very well with our strategy of ‘Green Mobility.’”

“Lanxess’ achievement proves how quickly bio-based monomers can be integrated into world-scale polymer production plants when you deliver the exact same performance for an existing, high-volume chemical,” said Christophe Schilling, Ph.D., CEO of Genomatica. “This is additional proof that we got the details right.”

Source: http://www.genomatica.com/

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.